logo-loader

Mindset Pharma says it has expanded benchmark data for psychedelics under COPE program with InterVivo Solutions

Published: 09:30 14 Oct 2021 EDT

Mindset Pharma Inc -
Mindset is focused on creating optimized and patentable psychedelic medicines for treating neurological and psychiatric disorders

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has developed its first-generation psychedelics benchmark data under the Co-operative Psychedelics Evaluation Platform (COPE) program in collaboration with InterVivo Solutions, a preclinical contract research organization.

The Toronto-based psychedelic company said that its benchmark data was determined by establishing standard pharmacokinetic (PK), brain penetration, and drug discrimination data and protocols for LSD, psilocybin, and 5-MeO-DMT.

"This data represents an additional step toward new drug discovery, and a potential market opportunity to provide peers with the ability to measure their NCEs against first-generation compounds,” said James Lanthier, CEO of Mindset in a statement. “The COPE program is enabling us to rapidly develop a pipeline of next-generation drugs, which we believe will be proven essential for the treatment of neuropsychiatric and neurological diseases in the near future.”

READ: Mindset Pharma identifies additional next-generation 5-MeO-DMT-inspired lead candidates

The COPE program was developed to establish industry standards for assessing the performance and efficacy of psychedelic medicines.

Mindset and InterVivon together “have generated standard PK and brain penetration data for LSD, psilocybin, and 5-MeO-DMT, and developed analytical procedures to determine concentrations of the drugs and active metabolites, such as psilocin and bufotenine, in plasma, brain and cerebral spinal fluid,” Joseph Araujo, Mindset chief scientific officer said.

He noted that the organization has trained cohorts of rats to discriminate psilocybin from saline, and standard generalization curves have been established for both orally and subcutaneously administered psilocybin.

“The development of rat cohorts capable of distinguishing several compounds represents a significant development for the industry as a whole, as it will allow drug developers to establish both the perceptual time-course and nuances of novel NCEs,” Araujo added. Studies for quantifying 5-HT2A receptor occupancy in the brain are also underway.

The company said it is planning on conducting further PK and brain penetration studies with DMT and psilocin, as well as establish cohorts of rats to discriminate 5-MeO-DMT from saline.

Mindset is focused on creating optimized and patentable psychedelic medicines for treating neurological and psychiatric disorders including severe depression, post-traumatic stress disorders, and addiction. The organization is working to develop ways for chemically synthesizing psilocybin as well as its compound.

Contact the author at ritika@proactiveinvestors.com

Mindset Pharma discusses decision to expand into non-hallucinogenic drug...

Mindset Pharma CEO James Lanthier joins Natalie Stoberman from the Proactive studios to discuss the company's latest update to expand into non-hallucinogenic therapeutic drug discovery. Lanthier says Mindset has been one of the first biotech companies in the psychedelic space to apply state...

on 03/30/2023